Business Description
Fusion Antibodies PLC
ISIN : GB00BDQZGK16
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 27.88 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -3.63 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -50.4 | |||||
3-Year EBITDA Growth Rate | -20.8 | |||||
3-Year EPS without NRI Growth Rate | 30.1 | |||||
3-Year FCF Growth Rate | 18.4 | |||||
3-Year Book Growth Rate | -53.2 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.47 | |||||
9-Day RSI | 54 | |||||
14-Day RSI | 56.27 | |||||
6-1 Month Momentum % | -24.36 | |||||
12-1 Month Momentum % | -46.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.87 | |||||
Quick Ratio | 3.09 | |||||
Cash Ratio | 2.05 | |||||
Days Inventory | 156.9 | |||||
Days Sales Outstanding | 135.8 | |||||
Days Payable | 133.93 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -55 | |||||
Shareholder Yield % | -66.14 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -3.96 | |||||
Operating Margin % | -201.32 | |||||
Net Margin % | -195.95 | |||||
FCF Margin % | -155.72 | |||||
ROE % | -152.81 | |||||
ROA % | -102.11 | |||||
ROIC % | -213.99 | |||||
3-Year ROIIC % | -35.58 | |||||
ROC (Joel Greenblatt) % | -302.65 | |||||
ROCE % | -151.49 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.22 | |||||
PB Ratio | 2.1 | |||||
Price-to-Tangible-Book | 2 | |||||
EV-to-EBIT | -1.17 | |||||
EV-to-EBITDA | -1.3 | |||||
EV-to-Forward-EBITDA | -2.81 | |||||
EV-to-Revenue | 2.34 | |||||
EV-to-Forward-Revenue | 2.43 | |||||
EV-to-FCF | -1.61 | |||||
Price-to-Net-Current-Asset-Value | 2 | |||||
Price-to-Net-Cash | 4 | |||||
Earnings Yield (Greenblatt) % | -85.72 | |||||
FCF Yield % | -46.37 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Fusion Antibodies PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 1.136 | ||
EPS (TTM) (£) | -0.045 | ||
Beta | 2.16 | ||
Volatility % | 108.8 | ||
14-Day RSI | 56.27 | ||
14-Day ATR (£) | 0.004903 | ||
20-Day SMA (£) | 0.03735 | ||
12-1 Month Momentum % | -46.36 | ||
52-Week Range (£) | 0.028 - 0.095 | ||
Shares Outstanding (Mil) | 95.37 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Fusion Antibodies PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Fusion Antibodies PLC Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
Fusion Antibodies PLC Frequently Asked Questions
What is Fusion Antibodies PLC(LSE:FAB)'s stock price today?
When is next earnings date of Fusion Antibodies PLC(LSE:FAB)?
Does Fusion Antibodies PLC(LSE:FAB) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |